Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Adenocarcinoma of the Prostate
Intervention: Bicalutamide (Casodex) (Drug)
Phase: N/A
Status: No longer available
Sponsored by: AstraZeneca
Summary
This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects
with prostate cancer prior to it becoming commercially available. The patient will receive
bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this
therapy and safety information is provided regularly to AstraZeneca. Treatment will be
discontinued after bicalutamide 150-mg becomes commercially available.
Clinical Details
Official title: A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer
Study design: N/A
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Patients with adenocarcinoma of the prostate
- Subjects with locally advanced, and/or metastatic prostate cancer for whom surgical
castration or other medical interventions are not considered appropriate or
acceptable
Exclusion Criteria:
- Any known history of abnormal liver function tests
- Any severe concomitant condition that would make it undesirable, in the clinician's
opinion, for the subject to participate in the trial.
- Known hypersensitivity to bicalutamide or any of the components found in bicalutamide
Locations and Contacts
Additional Information
Last updated: June 10, 2008
|
